T-cell engagement with a difference
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
CytomX shifts towards EpCAM
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
